In abstract it is stated that you also look at " ustekinumab"; however, I cannot find any data on this. The wording predictors is used in manuscript rather use prognostic factors which is more appropriate with regard to the study design. Why is the study period [2005] [2006] [2007] [2008] [2009] [2010] ? -this should be justified and discussed. ITT population is used but you require at least 1 MDA recording at follow-up. This introduces an attrition bias. So its actually more a per protocol/or as observed study rather than an ITT. Please revise wording used in manuscript, and discuss the implications of this. If sample size allows, please add as a sensitivity analysis patients with sustained MDA -i.e. at both 6 and 12 months. Patients with flare up (MDA at 6 but not 12 months) and patients with dropout between 6 and 12 months. Do these patients differ in background characteristics? Please describe how the multivariate regression model was constructedz section, however, it is clearly stated that participants included PsA patients receiving IFX or GLM. Therefore, no data on patients receiving UST are presented in this paper (the reason being the low number of patients with sufficient follow-up at this point). 2. Wording of predictors will be changed to prognostic factors. 3. The study period is not 2005-2010 but rather patients were enrolled in the registry since 2005 for IFX and since 2010 for GLM which is indicative of when these treatments were approved in Canada. In order to avoid confusion to the readership, the wording in the abstract will be adjusted to read "223 PsA patients treated with IFX (enrolled since 2005) or GLM (enrolled since 2010), with …". 4. We agree with the reviewer that this is a modified ITT population. As per the Reviewer"s suggestion, we will replace "ITT" with "As Observed". 5. Sustained MDA was reported in our manuscript, though the sample size did not allow for statistical comparisons in background characteristics or identification of prognostic factors, we therefore simply described what proportion of patients had sustained MDA. 6. Information on the multivariate model is already included in the footnote under Table 3B ( Over all this is a well written paper. I agree with the hypothesis, methodology and results of this study. A minor comment both the result section and the discussion section can be reduced; together the text of the manuscript can be reduced by 10-15% from its current status.
Author Response:
We are glad to hear that the Reviewer is satisfied with our manuscript. In the revised version we will also reduce the discussion sections by 10-15% as suggested by the reviewer.
Reviewer #3:
Reviewer Name: Philip Helliwell Institution and Country: University of Leeds, UK Competing Interests: I am an originator of the MDA This is a nice report of "real life" outcomes of patients in a restricted Canadian biologic registry. The authors are constrained by the available data and a glaring hole in this data is the lack of a 66/68 swollen and tender joint count. As the main outcome of interest is based on just such a count then, unfortunately, this comparison and analysis becomes invalid.
Author Response:
We understand the reviewer"s point, however unfortunately this is a limitation of the way that the data are collected within our registry. Given that: (i) prior studies (e.g. Englbrecht M et al. Arthritis Care Res (Hoboken). 2010 Jul;62(7):977-83) have shown that simplified joint counts are sufficiently sensitive to measure clinical response in PsA patients, and (ii) we already clearly acknowledge in the Discussion section the limitation of using 28-joint counts rather than 66/68 counts, and in consideration that this one of the first studies validating MDA in real-world we believe that our study will be of great interest to the readership of BMJ Open and merits publication. The study is informative well written and interesting, but could be improved considerably by adding additional analysis, by also using DAPSA remission, CPDAI/PASDAS if the data allows for this.
Moreover, it would be interesting if modified MDA by having Skin & swollen joints as mandatory criterias out of the 5/7! Data and statistics on agreement and predictabilities on these measures would be of great interes to the community.
Moreover, did a protocol exist and where can it be accessed.
Finally I would like a drop-out analysis to see how different the proportion of patients with missing data were -in order to illustrate degree of selection bias An Analysis from a Prospective, Observational, Biological Treatment Registry" with great interest. The study is informative well written and interesting, but could be improved considerably by adding additional analysis, by also using DAPSA remission, CPDAI/PASDAS if the data allows for this.
Author"s Response: Additional analyses have been conducted to evaluate DAPSA remission. Results have now been included in the manuscript to illustrate these findings. Unfortunately, Dermatology Life Quality Index (DLQI) and SF-36 are not collected in the BioTRAC registry. As such, the CPDAI and PASDAI could not be assessed in this analysis.
2. Moreover, it would be interesting if modified MDA by having Skin & swollen joints as mandatory criterias out of the 5/7! Author"s Response: Modified MDA as per the reviewer"s suggestion (skin and swollen joints as mandatory criteria) has been calculated and added to the manuscript. A manuscript addressing this question is also under preparation.
3. Data and statistics on agreement and predictabilities on these measures would be of great interest
